BBLG Offers Good Entry Opportunity
NASDAQ:BBLG
READ THE FULL BBLG RESEARCH REPORT
There are approximately 350,000 spinal fusion surgeries done in the US every year with varying degrees of success in alleviating often debilitating back pain. The existing dominant technology, known as rhBMP, has been quite successful in advancing the spinal fusion procedure but there are also challenges that can come along with using that technology. Patients can experience such impacts as rapid, uncontrolled bone growth that causes an unsound structure and unwanted bone formation where bone will grow where it is not intended. Back pain impacts 65 million Americans, with 16 million of those having what would be considered chronic back pain, leading to an estimated $12 billion per year in health care and indirect cost according to the Georgetown Policy Institute. While spinal fusion surgery isn’t the appropriate treatment for every kind of back pain, it can help to relieve the pain associated with a variety of conditions.
The NELL-1 technology is the centerpiece of what Bone Biologics (NASDAQ:BBLG) is developing. It was developed by UCLA TDG and Bone holds the exclusive worldwide rights to that technology. NELL-1 has been reviewed positively in over 45 peer reviewed publications demonstrating technological viability. NELL-1 has shown spine fusion effectiveness across three animal species—rodent, sheep and nonhuman primate and has competed two clinically relevant sheep studies that demonstrated NELL-1 increases the fusion rate and quantity of bone compared to the control group.
Bone Biologics recently announced that it has received approval to begin pilot clinical trials with NB1 in spinal fusion patients. The approval was given by the Human Research Ethics Committee and the trials will take place in Australia. This is an important and exciting step for Bone as the study will evaluate the safety and effectiveness of the company’s bone graft product—NB1. The study will include 30 adults who undergo transforaminal lumbar interbody fusion to treat degenerative disc disease. Importantly, this study design has been reviewed by the FDA’s Division of Orthopedic Devices and is intended to support progression to a clinical study in the US.
That brings us to the 3Q earnings update from Bone. The earnings aren’t so important to pay attention to as we know the company is in a research and development mode and not in the revenue generating mode. But the cash on hand is very important, and even more so at the present time when credit markets have tightened. Cash on hand at the end of 3Q was just under $4.5 million, which the company notes is sufficient to fund through the company through the 2nd quarter of 2024, when it is expecting to report results from the pilot study mentioned above. If the results are positive, as we expect them to be based on preliminary studies done by the company, we expect the company to have no trouble obtaining further funding to continue the advancement of the NELL-1 technology.
Summary
We have written before about the market opportunity that BBLG has and it continues to grow. Investors have been slow to recognize the potential in our view but now, ahead of the human trials, is the opportunity to get in at what we view as a discounted price. If trial results are positive, as we believe they will be, the positive reaction in the investing community will likely be swift. We continue to be excited about the opportunity and the science behind NELL-1 and are looking forward to the human trials beginning this year. BBLG has what we believe is a product with great potential, addressing a market with seemingly insatiable demand and a solid funding situation, which is vital in this environment. As such, we believe investors with a longer-term investing horizon should take a look at BBLG.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
